![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.fiercepharma.com/pharma/despite-jjs-rybrevant-full-nod-fda-encourages-dizal-file-rival-lung-cancer-drug-accelerated
https://www.prnewswire.com/news-releases/golidocitinib-approved-in-china-as-first-in-class-jak1-only-inhibitor-for-the-treatment-of-relapsed-or-refractory-peripheral-t-cell-lymphoma-302176781.html
https://www.prnewswire.com/news-releases/sunvozertinibs-global-pivotal-wu-kong1b-study-meets-primary-endpoint-in-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302161228.html
https://www.prnewswire.com/news-releases/dizal-reveals-new-findings-from-biomarker-analysis-highlighting-sunvozertinib-as-an-effective-treatment-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302155056.html
https://www.prnewswire.com/news-releases/breakthrough-in-lung-cancer-treatment-dizal-to-unveil-groundbreaking-results-of-sunvozertinib-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-at-2024-asco-annual-meeting-302125904.html
https://www.prnewswire.com/news-releases/fda-grants-breakthrough-therapy-designation-to-sunvozertinib-for-the-first-line-treatment-of--patients-with-advanced-non-small-cell-lung-cancer-harboring-egfr-exon-20-insertion-mutations-302109862.html
https://www.prnewswire.com/news-releases/dizals-sunvozertinib-pivotal-study-results-published-in-the-lancet-respiratory-medicine-302013864.html
https://www.prnewswire.com/news-releases/dizal-impresses-with-its-differentiated-hematological-oncology-portfolio-at-2023-ash-302012271.html
https://endpts.com/dizal-presents-updated-phii-ptlc-data-plans-to-file-for-accelerated-approval-in-the-us-next-year/
https://www.fiercebiotech.com/biotech/high-tumor-response-astrazeneca-spinout-dizal-explores-fda-path-and-us-partner-ptcl-drug